FDA
-
-
-
-
-
-
-
Emergent BioSolutions Marks 10-Year Anniversary of the U.S. FDA Approval of NARCAN® Nasal Spray and Reinforces its Commitment to Increasing Naloxone Access
-
-
-
-
-
-
-
Emergent BioSolutions gets $56 million U.S. contract for smallpox vaccine
-
-
-
-
-
-
-
Emergent BioSolutions (EBS) Expands NARCANDirect to Offer KLOXXADO Nasal Spray 8 mg and Convenience Kits Amid Changes in Overdose Death Rate
-
-
-
-
-
-
-
Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg
-
-
-
-
-
-
-
Enrollment Starts in Africa CDC-Led MpOx Therapeutic Study (MOSA)
-
-
-
-
-
-
-
Emergent BioSolutions Reports Third Quarter 2024 Financial Results
-
-
-
-
-
-
-
Emergent BioSolutions Awarded Research and Development Option valued at $41.9 Million for continued Advanced Development and Procurement of Ebanga™ Treatment for Ebola
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

